Profile number 104326
Producer medical cannabis
30/08/2022 Date added
Located in
Germany
Also interesting for this region (s)
- Noord-Nederland
- Oost-Nederland
- Midden-Nederland
- West-Nederland
- Zuid-Nederland
General information
Sector
Engineering
Type of company
Pharmaceutical industry
Legal entity
Private limited company
Type of transaction
Shares
Life phase enterprise
Starting
Employees in FTE
< 5
Type of buyer
- Strategic acquisition
- Investor
Financial information
Turnover last financial year
€ 100.000 - € 250.000
Asking price
€ 2.500.000 - € 5.000.000
Earnings before taxes
€ 0 - € 100.000
Company history/background
Company history / background:
The company has approval for the construction of a high-tech facility in the central region of Portugal and is in the final stages of construction permitting. The facility has the capability to produce extremely high-quality medical cannabis in small batches for the premium segment of the largest market currently in Europe – Germany. The company is working on several partnerships with exclusive genetics suppliers worldwide in order to produce a crop that is not available anywhere else in Europe. The company has a 5-year distribution agreement in place with a German distributor ensuring the product is directly available to all pharmacies and wholesalers. By producing in Portugal, the company is able to remain competitive throughout all cycles of the market and has a long-term vision to establish itself as a European craft cannabis producer for the premium segment of the market. The company will begin cultivating for research purposes in March 2022 and is expected to begin generating revenue from the end of Q2 2022, selling small volumes of product under their own brand in the German market.
Company activities
Working with renowned cannabis designers the planned facility is able to produce the highest quality cannabis consistently and at a low cost. The Director of Cultivation has significant experience in producing high-end cannabis with a track record of beating expectations in yield and testing levels, as well as commissioning new facilities. We plan to begin testing our genetics in March 2022 and will begin selling product under our own brand at the end of Q2 2022 in Germany. We plan to have our own cultivation operation certified by the end of Q4 2022 with first crops expected in Q1 2023.Our phase 1 facility will be able to produce 200kg of high-end cannabis per month in full production and we have expansion phases set out up to 20t per year in three phases.
Unique selling points
The company is keeping abreast of the significant developments in the legal cannabis industry in Europe (Netherlands, Germany, UK, Italy, France and Portugal) in order to assert their access to the markets as they open up.
Overig:
- VISION To integrate European supply into the global cannabis market - founded on medical - prepared for recreational
- MISSION By controlling our own supply, create a top-end brand of medical and recreational cannabis in Europe
The Team:
The company works with a highly motivated team with medical, financial, regulatory and operational experience that works with their local partners and the Portuguese authorities. The three founders are taking hands-on management roles in the company and will be acting as Director of Finance, Medical Director and Director of Operations.
Other
The emerging European Cannabis market presents a great opportunity for young companies and for investors to be a part of an entirely new branch of business with enormous potential. The stigma attached to medicinal cannabis is fading away quickly, the benefits of the cannabis plant are becoming more obvious to patients, politicians and scientists. We are seeking partners who share our vision of supplying medical cannabis to a steadily growing number of patients in Germany and Europe. The company is currently funding a small funding round in the form of a convertible with attractive conditions in order to facilitate operational expenses as well as the two ongoing projects to pave the way for market entry. The company is currently seeking € 4m investment for the construction of the facility as well as initial operating expenses until break-even on a mix of debt and equity. Preference will be given to investors who participate in the convertible rounds
Producer medical cannabis
Region
Germany
Sector
Engineering
Type
For sale
Turnover
100.000 - 250.000
Overname
2.500.000 - 5.000.000